Table 3. Achilles heels of individual common regimens1.
| Optimized therapies | Achilles heel1 |
|---|---|
| 14 day clarithromycin triple therapy | Clar®>15% |
| 14 day metronidazole triple therapy | Met® >15% |
| 14 day concomitant therapy | Clari®-Met® dual® >15% |
| 14 day sequential therapy | Clari®-Met® dual® >5% |
| 14 day hybrid therapy | Clari®-Met® dual® >9% |
| 14 day fluoroquinolone triple therapy | Levo® >13% |
| 14 day fluoroquinolone bismuth quadruple therapy | Levo® >25%2 |
| 14 day bismuth quadruple therapy | Tetracycline resistance (rare), compliance |
| 14 day bismuth-furazolidone therapy | Furazolidone resistance (rare), compliance |
| 5 day fluoroquinolone sequential therapy | Levo® ∼20%2 |
1
=The resistance level at which treatment success falls below 90%
2
=The number of subjects receiving these regimens is low such that the estimate is only approximate